Developing Next-Gen NK Cells to Boost Safety & Potency for More Effective Cancer Therapies

• Developing strategies to enhance NK, persistence, migration, tumor-killing potential and improving safety profiles
• Exploring scalable platforms for making ex vivo cell manufacturing more efficient at reduced cost

Speakers:

Frank Borriello

CEO

Alloplex Biotherapeutics